Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma

NCT03250299 is registered in ClinicalTrials.gov with Basilea Pharmaceutica as lead sponsor.

NCT NCT03250299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03250299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Lead sponsor
Basilea Pharmaceutica
Phase
Phase 1
Overall status
Terminated
Start date
December 15, 2017
Completion date
August 24, 2022
Enrollment
26 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, mgmt-unmethylated glioblastoma